Core Insights - Sentiment plays a crucial role in the performance of small-cap med-tech stocks, particularly during their early commercialization phases [1] - Significant coverage decisions for Sight Sciences' TearCare dry eye treatment have positively influenced the company's outlook since the last update [1] Company Overview - Sight Sciences (SGHT) has made notable progress in its commercialization efforts, particularly with its TearCare product [1]